<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30225620</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-7217</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>172</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research and treatment</Title>                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>            </Journal>            <ArticleTitle>Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.</ArticleTitle>            <Pagination>                <MedlinePgn>703-712</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-4936-2</ELocationID>            <Abstract>                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (EFS) and overall survival (OS) were analyzed separately in local and loco-regional relapses and compared across the cohorts by Kaplan-Meier method. Relative survival was estimated and Poisson regression models, adjusted for clinically relevant prognostic factors, were fitted for excess mortality ratio calculation. Age-related survival trends were also explored.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1922 patients diagnosed with local relapse, 1032 (54%) EFS events and 931 (48%) deaths were registered. A significant improvement in EFS (p &lt; 0.001) and OS (p &lt; 0.001) was demonstrated in tumors that recurred locally in the years 1990-1999 and 2000-2014 compared with 1980-1989, regardless of age at relapse (≤ 60 years; &gt; 60 years). In women with loco-regional relapse, 557 out of 776 (72%) experienced a post-relapse event and 522 (67%) died. Significantly longer EFS and OS were seen over time in the whole group (p &lt; 0.001 and p = 0.003, respectively) and in younger (p &lt; 0.001; p &lt; 0.001) but not in older women (p = 0.55; p = 0.80). Relative survival was consistent with OS and a statistically significant decrease in mortality after loco-regional recurrence over time was seen only in women aged ≤ 60 years.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Survival after loco-regional failure of breast cancer has improved over time, especially in younger women.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Falato</LastName>                    <ForeName>Claudette</ForeName>                    <Initials>C</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4055-4764</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. claudette.falato@ki.se.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska University Hospital, CCK, R8:03, 17176, Stockholm, Sweden. claudette.falato@ki.se.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Taylor</LastName>                    <ForeName>Sara K</ForeName>                    <Initials>SK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, British Columbia Cancer Agency, Kelowna, BC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Szulkin</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden and Scandinavian Development Services, Danderyd, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nordblom</LastName>                    <ForeName>Axel</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eriksson</LastName>                    <ForeName>Louise</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sofiadis</LastName>                    <ForeName>Anastasios</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fredriksson</LastName>                    <ForeName>Irma</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Breast and Endocrine Surgery, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hartman</LastName>                    <ForeName>Johan</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bergh</LastName>                    <ForeName>Jonas</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Foukakis</LastName>                    <ForeName>Theodoros</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Breast Cancer Res Treat</MedlineTA>            <NlmUniqueID>8111104</NlmUniqueID>            <ISSNLinking>0167-6806</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Isolated local recurrence of breast cancer</Keyword>            <Keyword MajorTopicYN="N">Loco-regional recurrence of breast cancer</Keyword>            <Keyword MajorTopicYN="N">Loco-regionally recurrent breast cancer</Keyword>            <Keyword MajorTopicYN="N">Survival after loco-regional relapse of breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30225620</ArticleId>            <ArticleId IdType="doi">10.1007/s10549-018-4936-2</ArticleId>            <ArticleId IdType="pii">10.1007/s10549-018-4936-2</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>